GIFT Nifty Opening Update
GIFT Nifty opened today at 24,302.50. It is up 91.00 points (0.37%) from yesterday’s close of 24,286.00— so the trend is positive.
Indian equity markets concluded the week with a sense of caution, furthering their recent correction as high crude oil prices, increasing global bond yields, and ongoing geopolitical uncertainty weighed on investor sentiment. Volatility persisted at elevated levels, as benchmark indices attempted a recovery throughout the week, ultimately concluding Friday’s session with minimal change. Investors remained vigilant, closely observing global risk factors. For the week, the Nifty experienced a decline of approximately 0.47%, concluding at 24,252, while the Sensex fell by nearly 0.60%, finishing at 77,540.83. Meanwhile, the broader market exhibited a degree of resilience, as the SmallCap index increased by approximately 1.2%, while the MidCap index experienced a slight decline.
On Monday, the market is expected to commence on an upward trajectory, as indicated by the Gift Nifty index, which suggests a favourable opening. Gift Nifty was trading near the 24,329.50 mark, reflecting an increase of over 43.50 points from the previous close of Nifty futures. “Indian equity markets are set to begin the week on a cautious footing as persistent Middle East tensions and elevated crude oil prices continue to temper risk appetite. Crude prices remain firm, with WTI trading near $86 a barrel as markets brace for fresh U.S. sanctions against Iran amid an already prolonged geopolitical standoff. Early indications from GIFT Nifty futures, trading in the 24,300–24,350 range against the Nifty’s previous close of 24,252, suggest a largely flat to marginally positive start for domestic equities,” said Ponmudi R.
As the market indicates a favourable opening, certain stocks are expected to attract attention on Monday owing to their individual positive or negative catalysts.
Equities to Monitor:
- Reliance Industries – Mukesh Ambani-led Reliance Industries announced that shareholders granted approval for three resolutions with the necessary majority on August 20. The resolutions encompass proposals pertaining to significant related-party transactions involving RIL and its subsidiaries.
- NATCO Pharma – The US Food and Drug Administration has released a Form 483 that includes four observations after conducting an inspection of the company’s finished dosage formulations facility located in Hyderabad. The inspection occurred from August 17 to August 21, 2026.
- Power Grid Corporation of India has successfully secured the bid through the Tariff Based Competitive Bidding process for the establishment of an inter-state transmission system aimed at facilitating renewable energy initiatives in Gujarat.
- JSW Infrastructure has entered into a share purchase agreement with JSW Terminal (Middle East) FZE and JSW Overseas FZE to acquire the complete 100% shareholding of JSW Overseas from JSW Terminal.
- Kaynes Technology India and BOSGAME have entered into a strategic memorandum of understanding aimed at establishing and enhancing BOSGAME’s footprint in the Indian market.
- Apollo Micro Systems announced that the manager of its open offer has received a communication from the Securities and Exchange Board of India regarding the proposed open offer to acquire up to 1.40 crore fully paid-up equity shares of Premier Explosives.
- Federal Bank – Kerala-based private sector lender Federal Bank announced that its board has approved a proposal to raise up to $500 million via the issuance of foreign currency-denominated bonds.
- Indian Renewable Energy Development Agency has established September 11, 2026, as the record date for identifying shareholders entitled to the proposed final dividend of Rs 0.75 per equity share for FY26.
- Diamond Power Infrastructure has obtained a letter of intent/order amounting to Rs 52.86 crore, inclusive of GST, from Aurionpro Solutions for the provision of high- and low-tension electrical cables to a hyperscale data center campus located in Hyderabad.
- Choksi Laboratories company announced that the US FDA finalised an inspection of its central laboratory located in Indore, Madhya Pradesh, from August 17 to August 20, 2026. The inspection yielded four observations.
